BR100 Increased By (0.31%)
BR30 Increased By (0.12%)
KSE100 Decreased By (-0.12%)
KSE30 Decreased By (-0.32%)
BECO 5.91 Decreased By ▼ -0.12 (-1.99%)
BML 57.61 Increased By ▲ 4.86 (9.21%)
BOP 33.91 Decreased By ▼ -0.34 (-0.99%)
CNERGY 8.18 Increased By ▲ 0.02 (0.25%)
DCL 11.79 Decreased By ▼ -0.55 (-4.46%)
FCCL 53.80 Decreased By ▼ -0.09 (-0.17%)
FCSC 5.35 Increased By ▲ 0.13 (2.49%)
FFL 17.89 Decreased By ▼ -0.14 (-0.78%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.22 Increased By ▲ 0.22 (2%)
KEL 8.10 Decreased By ▼ -0.01 (-0.12%)
KOSM 5.47 Increased By ▲ 0.09 (1.67%)
MLCF 88.20 Increased By ▲ 0.15 (0.17%)
NBP 183.74 Decreased By ▼ -2.74 (-1.47%)
PACE 11.50 Increased By ▲ 0.78 (7.28%)
PAEL 40.55 Increased By ▲ 0.61 (1.53%)
PIAHCLA 26.20 Increased By ▲ 0.03 (0.11%)
PIBTL 17.27 Decreased By ▼ -0.05 (-0.29%)
PPL 231.48 Decreased By ▼ -1.30 (-0.56%)
PRL 34.67 Decreased By ▼ -0.28 (-0.8%)
PTC 67.49 Decreased By ▼ -0.07 (-0.1%)
SEARL 91.45 Increased By ▲ 0.52 (0.57%)
SSGC 26.99 Decreased By ▼ -0.18 (-0.66%)
TELE 8.63 Increased By ▲ 0.06 (0.7%)
THCCL 65.00 Increased By ▲ 4.87 (8.1%)
TPLP 9.42 Increased By ▲ 0.66 (7.53%)
TREET 24.68 Increased By ▲ 0.14 (0.57%)
TRG 71.91 Increased By ▲ 0.16 (0.22%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)

LAHORE: Getz Pharma manufactures safe and efficacious medicines in its WHO, PIC/s, and EAEU pre-qualified manufacturing facility, a spokesman of the company, said.

Responding to false information about its product Risek IV 40 mg injection on electronic and social media, the spokesman said. “On February 12, 2024, the Federal Inspector of Drugs-IV, while conducting market surveillance in Moro, Sindh, identified counterfeit Risek 40mg IV injections at the premises of M/s Qalanari Medicos on Hospital Road, Moro, Nowsheroferoz.

Samples were sent for testing, including confirmation by Getz Pharma. We confirmed the sample as counterfeit, not manufactured by us, and provided a comparative analysis report to authorities, urging action.”

Getz Pharma condemns the misreporting by the electronic media of the Alert issued by Drug Regulatory Authority of Pakistan (DRAP) as if our manufactured product was deemed spurious or counterfeit, requiring recall.

Copyright Business Recorder, 2024

Comments

Comments are closed for this article.